Antiphospholipid Antibody Syndrome. Rare Diseases of the Immune System

18. New Treatments

Cecilia Beatrice Chighizola1, 2   and Tania Ubiali1, 3

(1)

Department of Clinical Sciences and Community Health, University of Milan, Via Festa del Perdono 7, Milan, 20122, Italy

(2)

Immunology Research Laboratory, IRCCS Istituto Auxologico Italiano, Via Zucchi 18, Cusano Milanino, Milan, 20095, Italy

(3)

Division of Rheumatology, Istituto Ortopedico Gaetano Pini, Piazza Cardinal Ferrari 1, Milan, 20122, Italy

Cecilia Beatrice Chighizola

Email: cecilia.chighizola@unimi.it

18.1 Introduction

Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by vascular thrombosis and/or pregnancy morbidity in the persistent presence of circulating antiphospholipid antibodies (aPL). Clinical management of APS patients aims not only at avoiding thrombotic and/or obstetric recurrences but also at preventing aPL-related complications as nephropathy, central nervous system involvement, and atherothrombosis. The cornerstone of APS treatment is still provided by drugs that counteract the aPL-mediated prothrombotic effects by preventing coagulation, namely, antiplatelet and anticoagulant agents. There is consensus that patients with venous events should receive long-term anticoagulation with vitamin K antagonists (VKA), while subjects who develop a stroke and present a low-risk aPL profile without any associated autoimmune condition may be prescribed with low-dose aspirin (LDASA); stroke patients at higher thrombotic risk and individuals with a history of noncerebral arterial thrombosis should receive long-term anticoagulation. A regimen combining preconceptional LDASA and low molecular weight heparin (LMWH) provides the first-line treatment for obstetric APS [12].

However, available treatments present several pitfalls. VKA, as well as LMWH, exert a strong impact on the quality of life of patients. The first agents necessitate frequent INR monitoring, as VKA interact with infections, exercise, smoking, alcohol, foods, and drugs; the latter requires a daily subcutaneous administration. In addition, despite adequate treatment, a significant rate of APS patients develops recurrences: the cumulative incidence of thromboembolic events at 10 years was 44 % in a cohort of triple positive APS patients. Remarkably, rethromboses provide the most common cause of death in APS [3]. Similarly, approximately 30 % of pregnant APS women receiving standard care have a poor obstetric outcome, with any alternative strategy being effective in this setting. Anticoagulation also carries a significant bleeding risk: a systematic review reported a major bleeding rate in APS patients on VKA between 0.57 and 10 % per year [4].

It clearly emerges that novel pharmacological tools are strongly warranted in APS to overcome the limitations of available treatments. A potential strategy consists in considering drugs implementing the anticoagulant and antiplatelet effect of standard treatment: new oral and nonoral anticoagulants, hydroxychloroquine (HCQ), and statins. Alternatively, the therapeutic approach could be completely modified using molecules modulating the interaction of aPL with their molecular targets and counteracting their downstream cellular effects. Potential pharmacological strategies include modulation of B cell and complement activation, receptor antagonism, and inhibition of aPL-induced intracellular and extracellular mediators such as NFκB, p38MAK, tissue factor (TF), interleukin (IL)-6, and tumor necrosis factor (TNF)-α [5]. Surely, a deeper unraveling of APS pathogenic mechanisms may allow identifying additional alternative therapeutic targets (Fig. 18.1).

A322602_1_En_18_Fig1_HTML.jpg

Fig. 18.1

Mechanisms of action of potential future therapeutic tools in APS. ROS reactive oxygen species, β2GPI β2 glycoprotein I, aβ2GPI antibodies against β2GPI, PDI protein disulfide-isomerase, ACEiangiotensin-converting enzyme inhibitors, TLR toll-like receptor, TF tissue factor, eNOS endothelial nitric oxide synthase, GP glycoprotein

18.2 aPL-Mediated Pathogenic Mechanisms

aPL are a heterogeneous family of autoantibodies reacting against proteins with affinity for negatively charged phospholipids (PL). In particular, beta-2 glycoprotein I (β2GPI) provides, together with prothrombin, the most important epitope targeted by aPL. Three configurations of β2GPI have been described: circulating plasma β2GPI exists in a circular form; upon binding to suitable anionic surfaces as cardiolipin (CL) and other PL or to LPS, the molecule opens into a J-shaped fishhook configuration; recently an intermediate S shape of β2GPI has been observed. β2GPI consists of 5 domains (D): DI-IV comprise 60 amino acids and contain two disulfide bridges each, while DV is aberrant, as it includes 82 amino acids due to a 6-residue insertion and a 19-residue C-terminal extension cross-linked by an additional disulfide bond. DI has been identified as the most relevant antigenic target involved in β2GPI/anti-β2GPI antibody binding. This epitope is a cryptic and conformation-dependent structure: in the circular conformation of β2GPI, DI interacts with DV and the critical epitope is thus hidden. When β2GPI adopts the S shape, the epitope is covered by DIII–IV carbohydrate chains, thus preventing antibodies from binding β2GPI. Upon opening to a J configuration, the critical epitope is exposed, becoming available for antibody binding. Several factors might lead to the surface exposition of the critical epitope, such as oxidative stress. Indeed, under oxidative conditions, disulfide bonds form in the molecule leading to the unmasking of the critical B-cell structure [6].

aPL exert a thrombogenic effect by interfering with both soluble components and cells involved in the coagulation cascade [5]. aPL promote aggregation and activation of platelets, neutralizing β2GPI interaction with von Willebrand factor and enhancing the expression of platelet membrane glycoprotein (GP) IIb/IIIa. Moreover, aPL induce a proinflammatory and procoagulant endothelial phenotype upregulating cellular adhesion molecules, promoting the synthesis of endothelial nitric oxide synthase (eNOS) and of proinflammatory cytokines as IL-6 and TNF-α. Lastly, aPL have been shown to significantly increase in both ECs and monocytes the expression of TF, the major initiator of the clotting cascade. Many molecules have been advocated as potential mediators of β2GPI interaction with target cells: annexin A2, toll-like receptor (TLR) 2 and 4, heparan sulfate, and ApoER2’. There is general agreement that NFκB and p38MAPK are involved in the downstream signaling pathways engaged by aPL [7].

aPL exert a thrombophilic effect also at a placental level, inducing intraplacental thrombosis and infarction, leading to an impairment of the maternal-fetal blood exchange. aPL were also shown to contribute to the prothrombotic state by activating complement and disrupting the anticoagulant annexin A5 shield on trophoblast and endothelial cell (EC) monolayers [7].

Hereby, cutting-the-edge therapeutic strategies are widely discussed, presenting the pioneer reports about the efficacy of novel pharmacological agents in APS based on the recent advances in understanding of aPL pathogenic mechanisms.

18.3 Novel Nonoral Anticoagulants

Fondaparinux and idraparinux are synthetic pentasaccharides homologous to heparin-binding site; their activity is limited on factor Xa. Both administered subcutaneously, fondaparinux is given daily, whereas idraparinux has a longer half-life, which allows a weekly administration. Given the low affinity to platelet factor 4, fondaparinux and idraparinux can be safely prescribed to patients with a history of heparin-induced thrombocytopenia. Fondaparinux has been licensed for VTE prophylaxis; idraparinux has not yet been patented: even though it was as effective as warfarin in preventing recurrence, it was associated with a significantly higher bleeding rate. Neither fondaparinux nor idraparinux has been yet evaluated in the setting of APS [8].

18.4 Novel Oral Direct Anticoagulants

Most recently, a novel class of anticoagulants has been synthesized: all administered orally, such pharmacological agents inhibit a single enzyme of the coagulation cascade, being thus called direct oral anticoagulants (DOA). Dabigatran is a potent, competitive, reversible direct thrombin inhibitor, which binds to thrombin and blocks its interaction with substrates. Direct FXa inhibitors include rivaroxaban, apixaban, and edoxaban. All these agents are highly selective, reversible, competitive, and dose dependent. They represent an advance over VKA mainly in terms of a better quality of life for patients: since they display a predictable anticoagulant effect, DOA are administered at a fixed dose. In addition, not being metabolized by the cytochrome P450 system, they do not interact with dietary constituents or alcohol and have few reported drug interactions, therefore not requiring routine monitoring of anticoagulant intensity. However, these novel DOA do not allow overcoming some other limitations affecting treatment with VKA. The main issue lies in the significant bleeding risk that any anticoagulant regimen carries and in the absence of an available pharmacological reversal agent [9].

The role of these emerging anticoagulants in APS management is still to be determined: there are three ongoing randomized controlled clinical trials evaluating rivaroxaban in the management of APS, as compared to low-intensity anticoagulation. The RAPS trial has been promoted by a UK group; it is a phase II/III study that has recruited 156 APS patients with a history of venous thromboembolism. A Spanish phase III trial has been started in Spain on 218 patients with venous or arterial events [10]. Most recently, an Italian trial considering triple positive APS patients only is going to start recruiting.

18.5 Hydroxychloroquine

HCQ is an antimalarial drug with anti-inflammatory and antithrombotic properties. In addition, HCQ has been shown to exert immunomodulatory effects: it prevents activation of TLR3, TLR7, and TLR9; inhibits antigen processing and presentation; and reduces circulating immune complexes [1112]. In in vitro models of thrombotic APS, HCQ has been demonstrated to inhibit GPIIb/IIIa expression on aPL-activated platelets [13], to reverse the formation of aPL-β2GPI-PL bilayer complexes [14], and to prevent the aPL-induced disruption of the annexin A5 shield [15]. Its antithrombogenic properties have been confirmed in in vivo models of APS: HCQ injection in mice induced a dose dependent decrease in thrombus size [16]. HCQ might be effective even in obstetric APS, as it was shown to reverse the binding of aPL to human placental syncytiotrophoblasts [17] and the aPL-inhibition of trophoblast IL-6 secretion [18].

Clinical data on the effectiveness of HCQ in preventing aPL-related thrombotic events have been derived from studies in SLE cohorts. Recently, a cross-sectional study on 77 APS patients and 56 asymptomatic aPL carriers from an SLE registry proved that the probability of a thrombotic event was decreased by LDASA or HCQ use [19]. In a still unpublished work, Petri and coworkers observed a decrease in arterial as well as venous thrombosis in aPL-positive lupus patients receiving HCQ [20].

In primary thrombotic APS, HCQ has been to date evaluated as an adjunctive pharmacological tool: patients receiving a combo regimen comprising HCQ plus oral anticoagulation experienced less recurrences compared to those on anticoagulants only. However, the extrapolation of data is affected by the limitations biasing this work: the study cohort was limited to 40 patients, and the follow-up lasted 36 months only [21]. HCQ is currently catalyzing much attention in APS: an ongoing study is assessing the effect of HCQ on annexin A5 resistance assay in aPL patients with or without SLE; a randomized controlled trial promoted by the international research organization APS ACTION is evaluating HCQ in the primary prevention of thrombosis in aPL asymptomatic carriers at 5 years of follow-up [22].

Even though there is limited clinical evidence of its antithrombotic effects in primary APS, treatment guidelines consider HCQ as a potential adjunctive therapy, particularly in consideration of its excellent safety profile [2].

18.6 Statins

Statins inhibit cholesterol synthesis in the mevalonate pathway by blocking the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase. The use of statins in the treatment of APS might thus be beneficial in the prevention of thrombosis since hypertriglyceridemia and low HDL cholesterol levels provide the most frequent cardiovascular risk factor reported in APS patients [23]. However, these pharmacological compounds have also been shown to exert a wide array of additional pleiotropic antithrombotic and anti-inflammatory effects in APS. In vitro, fluvastatin, simvastatin, and rosuvastatin have been demonstrated to inhibit TF synthesis in EC [24]; fluvastatin and simvastatin were both reported to suppress anti-β2GPI antibody-induced endothelial adhesiveness and to reduce monocyte adhesion to the endothelium [25], while rosuvastatin inhibited the upregulation of VCAM induced by aPL [26]. In vivo, fluvastatin reduced the size of the thrombus induced by aPL infusion and the leukocyte adhesion to EC. In models of obstetric APS, pravastatin did not prevent aPL-mediated functional effects on human trophoblasts in vitro [27], while in vivo simvastatin and pravastatin reduced fetal death [28]. These findings have been later confirmed in ex vivo studies. A trial in 42 patients with APS treated with fluvastatin for 30 days reported a decline in several thrombogenic and inflammatory mediators in monocytes [29]. More recently, Erkan observed a significant reduction of half of the evaluated proinflammatory and procoagulant parameters (IL-1β, VEGF, TNF-α, IP10, CD40L, and TF) in a cohort of 41 aPL asymptomatic carriers after 3 months of treatment with fluvastatin [30].

As a whole, statins could have a role a potential treatment for APS, beyond their lipid-lowering activity with no intrinsic additional risk of bleeding [31].

18.7 Vitamin D

In vitro, vitamin D exerts an antithrombotic and immunomodulator function by inhibiting β2GPI-mediated TF expression [32]. Retrospective studies indicated that the prevalence of vitamin D deficiency in APS patients ranges from 10 to 50 %, while insufficiency may occur in up to 70 % of patients [3236]. Low vitamin D levels correlate with arterial and venous thrombosis as well as with non-criteria APS manifestations [3234]. Conversely, most studies supported no association between low vitamin D levels and obstetric APS [3235]. Prospective studies are warranted to evaluate the therapeutic value of supplementation with vitamin D in aPL carriers.

18.8 Intravenous Immunoglobulins

In vivo and in vitro models suggest the therapeutic potential of intravenous immunoglobulins (IVIg) in APS. IVIg were shown to inhibit aPL, by partially neutralizing LA activity and preventing aCL binding to cardiolipin by Fab. IVIg exert an anti-idiotype activity, with inactivation of idiotype-bearing B-cell clones. Furthermore, IVIg have been demonstrated to increase IgG catabolism, to modulate complement activation, to block Fcγ receptor on macrophages, and to downregulate proinflammatory cytokines [37]. Treatment with IVIg resulted in an inhibition of aPL thrombogenic effects, with a reduction of circulating aCL levels [38]. There are few reports about successful treatment with IVIg in the management of aPL-related clinical manifestations, mainly hematogical (thrombocytopenia, hemolytic anemia, hypoprothrombinemia). Treatment response was observed in all cases but one [39]. Recently, IVIg were found to be effective in preventing recurrent thrombosis among five patients with refractory APS in a 5-year open study [40].

18.9 Rituximab

The pivotal role exerted by B cells in APS has been progressively deciphered: B lymphocytes contribute to APS etiopathogenesis by producing autoantibodies, inducing the formation of germinal centers and the synthesis of cytokines. Accordingly, in NZW x BXSB mice, treatment with IgG against B-cell activating factor (BAFF) receptor did not prevent the development of aCL even though it prevented aPL-related thrombotic vasculopathy, prolonging survival [41]. In the same murine models, IgG against cytotoxic T-lymphocyte antigen 4 immunoglobulin (CTLA4) affected initiation but not development of APS. These data suggest the potential efficacy of belimumab and abatacept in APS [42]. Interestingly, in belimumab-treated patients with systemic lupus erythematosus (SLE) a positive-to-negative conversion rate was reported for aCL [43]. To date, clinical experience of B-cell inhibitory agents specifically in APS patients are restricted to the use of rituximab, a chimeric monoclonal antibody targeting CD20 on the surface of B cells. Successful treatment with rituximab has been reported in anecdotal reports and in one case series from the BIOGEAS registry. In this multicenter Spanish registry, a therapeutic response was observed in 92 % of 12 cases [44]. In 2012, a review collected all the published cases, identifying 27 APS patients treated with rituximab [45]. The anti-CD20 monoclonal resulted in a decrease of aPL titers; among those receiving rituximab because of thrombotic recurrences, clinical improvement was observed in all cases. Moreover, rituximab was beneficial for a plethora of aPL-related clinical manifestations. At this regard, an open-label phase IIa descriptive pilot study (RITAPS) has been carried out in 20 patients with non-criteria APS manifestations refractory to conventional treatments [46]. Rituximab resulted to be effective in controlling some but not all non-criteria manifestations, without substantial change in aPL profile. Notably, caution should be paid to its use in APS: episodes of severe acute thrombotic exacerbations (lacunar infarctions and transverse myelitis) have been reported in two APS/SLE patients receiving rituximab [47].

Rituximab has been used in 20 cases of catastrophic APS (CAPS), in different combination with anticoagulation, high doses of steroids, plasma exchange, and IVIg. Despite the difficulties in determining the effects of rituximab, a lower mortality compared to larger series emerged [48].

18.10 Eculizumab

The complement system, in particular the mediator C5a, has been shown to play a central role in APS. C5a, a potent anaphylatoxic, proinflammatory, and chemotactic molecule, was demonstrated to induce the expression of TF on EC [49] and neutrophils [50]. In vivo, C5a was involved in deposition of fibrin in a growing thrombus induced by aPL injection [51]. C5a-induced recruitment and activation of neutrophils lead to trophoblast injury and angiogenic factor imbalance in aPL-induced fetal injury [52]. Eculizumab is a humanized monoclonal antibody which binds to the C5 protein with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of membrane attack complex [53]. In vivo, anti-C5 antibody was shown to attenuate thrombosis and to prevent aPL-mediated pregnancy loss [49]. To date, eculizumab has been administered to few CAPS patients in which all the other therapeutic strategies proved to be ineffective. A favorable response was described in two cases [5455] and a negative outcome in the others [22]. Eculizumab has also been investigated as a tool to manage APS patients after renal transplantation. In a first report on three consecutive kidney transplant recipients with posttransplant aPL-mediated thrombotic microangiopathy (TMA) resistant to plasmapheresis, treatment with eculizumab improved TMA [56]. In another case series of three patients treated with anticoagulation and eculizumab, no systemic thrombotic events or early graft losses were reported after a follow-up ranging from 4 months to 4 years [57].

18.11 Defibrotide

Defibrotide is a polydisperse mixture of 90 % single-stranded and 10 % double-stranded phosphodiester oligonucleotides derived from the controlled depolymerization of porcine intestinal mucosal DNA. This pharmacological compound acts by upregulating the release of prostacyclin and prostaglandin E2, reducing concentrations of leukotriene B4, inhibiting monocyte superoxide anion generation, stimulating expression of thrombomodulin in human vascular EC, and modulating platelet activity [58]. More recently, defibrotide was shown to downregulate TF expression on monocytes [59]. To date, it has been used in two patients with CAPS: in one case this treatment was successful, while the second patient died [6061].

18.12 Novel Molecules Blocking β2GPI/Anti-β2GPI Antibody Binding

TIFI is a 20 amino acid synthetic peptide that spans Thr101–Thr120 of ULB0-HCMVA from human cytomegalovirus, which shares similarities with the PL-binding site in β2GPI molecule, DV. TIFI is not targeted by aPL; in vitro evidence suggest that TIFI inhibits the binding of labeled β2GPI to human EC and mouse monocytes [62]. Similarly, the peptide prevented anti-β2GPI reactivity toward human trophoblast monolayers. These findings were also confirmed in animal models: the infusion of this synthetic peptide inhibited aPL-mediated thrombosis by decreasing the thrombus size produced in response to aPL and by reducing the binding of fluoresceinated β2GPI to EC. Pregnant naïve mice treated with TIFI were protected from fetal loss induced by human aPL IgG [63].

Accordingly, a synthetic β2GPI-DI was shown to inhibit aPL-mediated prothrombic effects both in vivo and in vitro [64].

MBB2 is a novel single-chain variable fragment (scFv)-Fc monoclonal antibody targeting DI of human, rat, and mouse β2GPI. When infused to experimental animals, MBB2 caused blood clots in rat mesenteric microcirculation after LPS priming. A non-complement-fixing variant of MBB2, MBB2ΔCH2, has also been developed. MBB2ΔCH2 displays the same antigen specificity of MBB2 but, lacking the CH2 domain, is unable to activate the complement cascade. MBB2ΔCH2 has been shown to prevent the aPL procoagulant effects in vivo by competing with circulating aPL for binding to β2GPI. In vivo, the CH2-deleted monoclonal antibody significantly reduced mesenteric thrombus formation and vessel occlusion [65].

Such antibody can be used in the future even in the management of obstetric APS, as MBB2ΔCH2 leaves bound β2GPI untouched. This is important because cell-bound β2GPI exerts a key role at the placental level, as supported by the defective embryo implantation and placental morphogenesis displayed by β2GPI−/− mice. Hence, any tool able to block the pathogenic effects of aPL leaving untouched β2GPI represents a useful approach.

It can also be postulated that antagonists of the receptors involved in β2GPI cell binding may exert a therapeutic potential [66]. The use of antagonists or neutralizing monoclonal antibodies acting on TLR2/4 might be speculated in APS. In addition, DV of β2GPI binds the A1 ligand-binding type A module of ApoER2’; a dimer composed of two A1 molecules joined by a flexible linker has been shown to inhibit anti-β2GPI antibody/dimerized β2GPI immune complexes from binding negatively charged PL and ApoER2’ in vitro, more potently than A1 in the monomeric form [67]. More recently, proofs of the effectiveness of this dimeric molecule were obtained in vivo, in two animal models of APS. Indeed, treatment with A1-A1 efficiently reduced thrombus size in vivo in the presence of chronic autoimmune anti-β2GPI antibody in lupus-prone (NZW3BXSB)F1 male mice as well as in wild-type mice after infusion with anti-β2GPI antibodies [68].

Similarly, blockers of the intracellular mediators involved in aPL-activated signaling pathways may reverse the prothrombotic phenotype: NFkB and p38MAPK inhibitors have been shown to be effective in preventing aPL-mediated prothrombotic and proinflammatory effects in vitro [69]. More recently, the NFkB inhibitor DHMEQ was demonstrated to ameliorate the prothrombotic state induced by the infusion of the monoclonal antibody WB-6 in normal BALB/c mice [70].

18.13 Novel Molecules Interfering with aPL-Induced Mediators

It is can be speculated that TF inhibition may prevent thrombosis in APS [71]. Currently, there are few drugs available on the market blocking TF expression: ACE inhibitors, dilazep, defibrotide, and dipyridamole. In particular, both dilazep and dipyridamole have been shown to block the upregulation of TF specifically induced by polyclonal IgG purified from APS patients in monocytes [7273]. However, their role in APS management has been scarcely documented. Dual antiplatelet treatment (different combination of LDASA, ticlopidine, clopidogrel, cilostazol) has been recently proposed: a Japanese study on 82 APS patients with refractory arterial events documented no recurrences among those subjects receiving two antiplatelet agents [74].

aPL also upregulate GPIIb/IIIa, thus leading to platelet aggregation. Abciximab is a specific GPIIb/IIIa inhibitor routinely prescribed in stroke and acute coronary syndromes, which might be beneficial in APS [75].

Protein disulfide-isomerase is the enzyme responsible of the formation of two disulfide bridges within β2GPI molecule, a reaction leading to an oxidized and immunogenic molecule. This enzyme is inhibited by quercetin-3-rutinoside, whose potential pharmacological effect in APS has to be investigated [76]. In animal models, inhibitors of PDI were effective in treating thrombosis [76].

Given that oxidation leads to the unmasking of the critical B-cell epitope, it might be worth exploring the role of antioxidant compounds as N-acetylcysteine, vitamin C, and coenzyme Q10 in APS [66]. In an in vitro study, the inhibition of intracellular reactive oxygen species in monocytes prevented the upregulation of TF induced by aPL [77]. Similarly, TNF-α and IL-6 are proinflammatory mediators induced by aPL: it is therefore reasonable to hypothesize that the blockade of these cytokines with biologic agents may be clinically beneficial. Interestingly, in a mice model anti-TNF-α agents proved to be protective against aPL-induced pregnancy loss [69].

18.14 Conclusions

Much research attention is currently focused at identifying novel pharmacological tools in APS: some of these compounds have already been used in clinical practice, although in many cases experience is yet limited to anecdotal reports. Some others are currently under evaluation in randomized clinical trial in order to test their efficacy in the setting of APS.

However, the impact of a tight control of traditional vascular risk factors on clinical outcome of APS patients has not been ascertained yet. At this regard, the pleiotropic effects of agents such as statins and HCQ should be further assessed: the addition of these drugs to standard anticoagulation may lead to a better disease control. Moreover, the identification of novel diagnostic tools, such as antibodies against domain I of β2GPI or against phosphatidylserine/prothrombin, may allow a more precise stratification of thrombotic risk, leading to a tailored treatment strategy.

Forthcoming years will be essential to understand whether the above cited agents might eventually revolutionize APS management.

References

1.

Lim W, Crowther MA, Eikelboom JW (2006) Management of antiphospholipid antibody syndrome. JAMA 295:1050–1057PubMedCrossRef

2.

Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I et al (2011) Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on Antiphospholipid Antibodies. Lupus 20:206–218PubMedCrossRef

3.

Cervera R, Serrano R, Pons-Estel GJ et al; On behalf of the Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies) (2014) Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. doi:10.​1136/​annrheumdis-2013-204838

4.

Les I, Ruiz-Irastorza G, Khamashta MA (2012) Intensity and duration of anticoagulation therapy in antiphospholipid syndrome. Semin Thromb Hemost 38:339–347PubMedCrossRef

5.

Meroni PL, Chighizola C (2012) Pathophysiology of the antiphospholipid syndrome (APS). Rev Med Interne 33:A2–A4PubMedCrossRef

6.

Chighizola CB, Gerosa M, Meroni PL (2014) New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies. Curr Rheumatol Rep 16:402PubMedCrossRef

7.

Meroni PL, Borghi MO, Raschi E et al (2011) Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 7:330–339PubMedCrossRef

8.

Alijotas-Reig J (2013) Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. Lupus 22:6–17PubMedCrossRef

9.

Chighizola C, Moia M, Meroni PL (2014) New oral anticoagulants in thrombotic antiphospholipid syndrome. Lupus 23:1279–82

10.

Giles I, Khamashta M, D’Cruz D et al (2012) A new dawn of anticoagulation for patients with antiphospholipid syndrome? Lupus 21:1263–1265PubMedCrossRef

11.

Petri M (2011) Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep 13:77–80PubMedCrossRef

12.

Kuznik A, Bencina M, Svajger U et al (2011) Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 186:4794–4804PubMedCrossRef

13.

Espinola RG, Pierangeli SS, Gharavi AE et al (2002) Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 87:518–522PubMed

14.

Rand J, Wu X, Quinn A et al (2008) Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 112:1687–1695PubMedCentralPubMedCrossRef

15.

Rand JH, Wu XX, Quinn AS et al (2010) Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 115:2292–2299PubMedCentralPubMedCrossRef

16.

Edwards MH, Pierangeli S, Liu X et al (1997) Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 96:4380–4384PubMedCrossRef

17.

Wu XX, Guller S, Rand JH (2011) Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression. Am J Obstet Gynecol 205:e7–e14PubMed

18.

Albert CR, Schlesinger WJ, Viall CA et al (2014) Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function. Am J Reprod Immunol 71:154–164PubMedCrossRef

19.

Erkan D, Yazici Y, Peterson MG et al (2002) A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 41:924–929CrossRef

20.

Law G, Magder LS, Fang H et al (2012) Hydroxychloroquine reduces thrombosis in systemic lupus erythematosus, particularly in antiphospholipid positive patients [abstract]. Arthritis Rheum 64:2569

21.

Schmidt-Tanguy A, Voswinkel J, Henrion D et al (2013) Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J Thromb Haemost 11:1927–1929PubMed

22.

Erkan D, Aguiar CL, Andrade D et al (2014) 14th international congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 13:685–696PubMedCrossRef

23.

Medina G, Gutiérrez-Moreno AL, Vera-Lastra O et al (2011) Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients. Autoimmun Rev 10:214–217PubMedCrossRef

24.

Ferrara D, Swerlick R, Casper K et al (2004) Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost 2:1558–1563PubMedCrossRef

25.

Meroni PL, Raschi E, Testoni C et al (2001) Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 44:2870–2878PubMedCrossRef

26.

Martínez-Martínez LA, Amigo MC, Orozco A et al (2006) Effect of rosuvastatin on vascular cell adhesion molecule 1 (vcam-1) expression by human endothelial cells exposed to antiphospholipid syndrome serum. J Clin Rheumatol 12:S80CrossRef

27.

Odiari EA, Mulla MJ, Sfakianaki AK et al (2012) Pravastatin does not prevent antiphospholipid antibody-mediated changes in human first trimester trophoblast function. Hum Reprod 27:2933–2940PubMedCrossRef

28.

Redecha P (2008) Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest 118:3453–3461PubMedCentralPubMed

29.

Lòpez-Pedrera C, Ruiz-Limòn P, Aguirre MÀ et al (2011) Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Ann Rheum Dis 70:675–682PubMedCrossRef

30.

Erkan D, Willis R, Vega JA et al (2012) An open-label prospective pilot mechanistic study of fluvastatin in persistently antiphospholipid antibody-positive patients. Arthritis Rheum 64:S1034

31.

Ruiz-Irastorza G, Crowther M, Branch W et al (2010) Antiphospholipid syndrome. Lancet 376:1498–1509PubMedCrossRef

32.

Agmon-Levin N, Blank M, Zandman-Goddard G et al (2011) Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis 70:145–150PubMedCrossRef

33.

Andreoli L, Piantoni S, Dall’Ara F et al (2012) Vitamin D and antiphospholipid syndrome. Lupus 21:736–740PubMedCrossRef

34.

Piantoni S, Andreoli L, Allegri F et al (2012) Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease. Reumatismo 64:307–313PubMedCrossRef

35.

Klack K, Carvalho JF (2010) High frequency of vitamin D insufficiency in primary antiphospholipid syndrome. Joint Bone Spine 77:489–490PubMedCrossRef

36.

Paupitz JA, Freire de Carvalho J, Caparbo VF et al (2010) Primary antiphospholipid syndrome in premenopausal women: low vitamin D, high fat mass and maintained bone mineral mass. Lupus 19:1302–1306PubMedCrossRef

37.

Konova E (2005) Intravenous Immunoglobulin therapy in anti-phospholipid syndrome. Clin Rev Allergy Immunol 29:229–236PubMedCrossRef

38.

Pierangeli SS, Espinola R, Liu X et al (2001) Identification of an Fc gamma receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype. Arthritis Rheum 44:876–883PubMedCrossRef

39.

Sherer Y, Levy Y, Shoenfeld Y (2000) Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology (Oxford) 39:421–426CrossRef

40.

Sciascia S, Giachino O, Roccatello D (2012) Prevention of thrombosis in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin. Clin Exp Rheumatol 30:409–413PubMed

41.

Kahn P, Ramanujam M, Bethunaickan R et al (2008) Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum 58:2824–2834PubMedCentralPubMedCrossRef

42.

Akkermann A, Huang W, Wang X et al (2004) CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice. Autoimmunity 37:445–451CrossRef

43.

Stohl W, Hiepe F, Latinis KM et al (2012) Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell population in patients with systemic lupus erythematosus. Arthritis Rheum 64:2328–2337PubMedCentralPubMedCrossRef

44.

Ramos-Casals M, Brito-Zeròn P, Muñoz S et al (2008) A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 87:345–364CrossRef

45.

Khattri S, Zandman Goddard G, Peeva E (2012) B-cell directed therapies in antiphospholipid antibody syndrome – new directions based on murine and human data. Autoimmun Rev 11:717–722PubMedCrossRef

46.

Erkan D, Vega J, Ramòn G et al (2013) A pilot open-label phase II trial of rituximab for non criteria manifestations of antiphospholipid syndrome. Arthritis Rheum 65:464–471PubMedCrossRef

47.

Suzuki K, Nagasawa H, Kameda H et al (2009) Severe acute thrombotic exacerbation in two cases with anti-phospholipid syndrome after retreatment with rituximab in phase I/II clinical trial for refractory systemic lupus erythematosus. Rheumatology (Oxford) 48:198–199CrossRef

48.

Berman H, Rodrìguez-Pintò I, Cervera R et al (2013) Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry. Autoimmun Rev 1:1085–1090CrossRef

49.

Ikeda K, Nagasawa K, Horiuchi T et al (1997) C5a induces tissue factor activity on endothelial cells. Thromb Haemost 77:394–398PubMed

50.

Ritis K, Doumas M, Mastellos D et al (2006) A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol 177:4794–4802PubMedCrossRef

51.

Fischetti F, Durigutto P, Pellis V et al (2005) Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 106:2340–2346PubMedCrossRef

52.

Lubbe WF, Butler WS, Palmer SJ et al (1983) Fetal survival after prednisolone suppression of maternal lupus-anticoagulant. Lancet 18:1361–1363CrossRef

53.

Schmidtko J, Peine S, El-Housseini Y et al (2013) Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab. Am J Kidney Dis 61:289–299PubMedCrossRef

54.

Lonze BE, Singer AL, Montgomery RA (2010) Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 362:1744–1745PubMedCrossRef

55.

Shapira I, Andrade D, Allen SL et al (2012) Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 64:2719–2723PubMedCrossRef

56.

Canaud G, Kamar N, Anglicheau D et al (2013) Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant 13:2179–2185PubMedCrossRef

57.

Lonze BE, Zachary AA, Magro CM et al (2014) Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant 14:459–465PubMedCrossRef

58.

Morabito F, Gentile M, Gay F et al (2009) Insights into defibrotide: an updated review. Expert Opin Biol Ther 9:763–767PubMedCrossRef

59.

Falanga A, Vignoli A, Marchetti M et al (2003) Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia 17:1636–1642PubMedCrossRef

60.

Asherson RA, Cervera R, Piette JC et al (2001) Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 80:355–376CrossRef

61.

Burcoglu-O’Ral A, Erkan D, Asherson R (2002) Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. J Rheumatol 29:2006–2011PubMed

62.

Ostertag MV, Liu X, Henderson V et al (2006) A peptide that mimics the Vth region of β2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice. Lupus 15:358–365PubMedCrossRef

63.

de la Torre YM, Pregnolato F, D’Amelio F et al (2012) Anti-phospholipid induced murine fetal loss: novel protective effects of a peptide targeting the beta-2 glycoprotein I phospholipid-binding site. Implication for human fetal loss. J Autoimmun 38:209–215CrossRef

64.

Ioannou Y, Romay-Penabad Z, Pericleous C et al (2009) In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost 7:833–842PubMedCrossRef

65.

Agostinis C, Durigutto P, Sblattero D et al (2014) A non complement-fixing antibody to b2 glycoprotein I as a novel therapy to control abortions and thrombosis in antiphospholipid syndrome. Blood. doi:10.​1182/​blood-2013-11-537704PubMed

66.

Giannakopoulos B, Krilis SA (2013) The pathogenesis of the anti-phospholipid syndrome. N Engl J Med 368:1033–1044PubMedCrossRef

67.

Kolyada A, Chang-Jin L, De Biasio A et al (2010) A novel dimeric inhibitor targeting Beta2GPI in Beta2GPI/antibody complexes implicated in antiphospholipid syndrome. PLoS One 5:e15345PubMedCentralPubMedCrossRef

68.

Kolyada A, Porter A, Beglova N (2014) Inhibition of thrombotic properties of persistent autoimmune anti-b2GPI antibodies in the mouse model of antiphospholipid syndrome. Blood 123:1090–1097PubMedCrossRef

69.

Comarmond C, Cacoub P (2013) Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies. Autoimmun Rev 12:752–757PubMedCrossRef

70.

Nishimura M, Nii T, Trimova G et al (2013) The NF-κB specific inhibitor DHMEQ prevents thrombus formation in a mouse model of antiphospholipid syndrome. J Nephropathol 2:114–121PubMedCentralPubMedCrossRef

71.

Pierangeli SS, Erkan D (2010) Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? Lupus 19:475–485PubMedCrossRef

72.

Zhou H, Wolberg AS, Roubey RA (2004) Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 104:2353–2358PubMedCrossRef

73.

Zhou H (2004) Dilazep and dipyridamole inhibit tissue factor expression on monocytes induced by IgG from patients with antiphospholipid syndrome. Acta Pharmacol Sin 25:1366–1371PubMed

74.

Fujieda Y, Amengual O, Watanabe T et al (2012) Dual antiplatelet therapy as prophylaxis of recurrent arterial thrombosis in patients with antiphospholipid syndrome. Arthritis Rheum 64:S1036

75.

Scoble T, Wijetilleka S, Khamashta MA et al (2011) Management of refractory anti-phospholipid syndrome. Autoimmun Rev 10:669–673PubMedCrossRef

76.

Jasuja R, Passam FH, Kennedy DR et al (2012) Protein disulphide isomerase inhibitors constitute a new class of antithrombotic agent. J Clin Invest 122:2104–2113PubMedCentralPubMedCrossRef

77.

Perez-Sanchez C, Ruiz-Limon P, Aguirre MA et al (2012) Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q10 treatment. Blood 119:5859–5870PubMedCrossRef